Simplify Logo

Full-Time

QAD Developer

Confirmed live in the last 24 hours

PROCEPT BioRobotics

PROCEPT BioRobotics

501-1,000 employees

Develops robotic solutions for BPH treatment

Biotechnology
Healthcare

Compensation Overview

$120k - $150kAnnually

+ Bonus + Equity/RSUs

Mid, Senior

No H1B Sponsorship

San Jose, CA, USA

This role is hybrid, offering flexibility to work partially from home while collaborating with teams across the organization.

Category
Backend Engineering
Software QA & Testing
Software Engineering
Required Skills
Inventory Management
SQL
Linux/Unix
Requirements
  • Bachelor’s degree in Computer Science or a related field.
  • 5+ years of relevant IT and/or business experience in the medical device, biotech, pharmaceutical, healthcare industry, or related consulting services.
  • Expertise in Progress ERP programming.
  • Experience with QAD .Net UI and Unix/Linux operating systems.
  • Experience with manufacturing modules (e.g., Forecast, MRP, Inventory Management, Production Orders, Quality Management).
  • Strong analytical and quantitative skills, with proficiency in SQL
Responsibilities
  • Collaborate with key stakeholders to translate business requirements into technical solutions.
  • Design, develop, implement, and maintain Progress 4GL/OpenEdge applications and code within the QAD application.
  • Provide ongoing technical support and troubleshooting for various business functions and processes.
  • Proactively communicate with stakeholders to identify and implement process improvements.
  • Prioritize and deliver on IT requests in collaboration with departments across the organization.
  • Ensure compliance with the PROCEPT BioRobotics Quality Management System and regulatory requirements.

PROCEPT BioRobotics develops robotic solutions specifically for treating benign prostatic hyperplasia (BPH), a condition that affects many older men by causing prostate enlargement and urinary issues. Their main product, the AquaBeam Robotic System, utilizes Aquablation therapy, which combines real-time imaging, robotics, and waterjet technology to precisely remove prostate tissue in a minimally invasive manner. This system is designed for urologists and healthcare facilities, allowing for improved patient outcomes and more efficient surgical procedures. Unlike competitors, PROCEPT BioRobotics focuses on providing predictable results and reducing complications, which has led to their technology being recognized in clinical guidelines. The company's goal is to enhance the quality of life for patients suffering from BPH through advanced surgical solutions.

Company Stage

IPO

Total Funding

$637.7M

Headquarters

Redwood City, California

Founded

2009

Growth & Insights
Headcount

6 month growth

10%

1 year growth

37%

2 year growth

112%
Simplify Jobs

Simplify's Take

What believers are saying

  • Long-term data demonstrating the sustained benefits of Aquablation therapy enhances the company's reputation and supports its market position.
  • Significant investments, including $118 million in equity financing, provide the financial resources needed for global expansion and innovation.
  • FDA approval for investigating Aquablation therapy for prostate cancer opens new market opportunities and potential revenue streams.

What critics are saying

  • Ongoing investigations by law firms into possible securities fraud could damage the company's reputation and investor confidence.
  • The medical device market is highly competitive, and maintaining technological leadership requires continuous innovation and substantial investment.

What makes PROCEPT BioRobotics unique

  • PROCEPT BioRobotics specializes in Aquablation therapy, a unique minimally invasive treatment for BPH that combines real-time imaging, robotics, and waterjet technology, setting it apart from traditional surgical methods.
  • The company's focus on urology and the treatment of BPH allows it to develop highly specialized and effective solutions, unlike competitors with broader medical device portfolios.
  • The inclusion of PROCEPT's technology in clinical practice guidelines underscores its credibility and effectiveness, distinguishing it from less established competitors.

Help us improve and share your feedback! Did you find this helpful?